Compare OPRA & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRA | NVAX |
|---|---|---|
| Founded | 1996 | 1987 |
| Country | Norway | United States |
| Employees | N/A | 1992 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2018 | 1996 |
| Metric | OPRA | NVAX |
|---|---|---|
| Price | $15.39 | $11.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $22.75 | $10.78 |
| AVG Volume (30 Days) | 708.3K | ★ 3.4M |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | ★ 6.41% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $27.78 | $58.91 |
| Revenue Next Year | $14.63 | N/A |
| P/E Ratio | $13.62 | ★ $3.77 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $11.71 | $5.01 |
| 52 Week High | $21.06 | $10.63 |
| Indicator | OPRA | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 74.43 |
| Support Level | $12.96 | $6.34 |
| Resistance Level | $15.50 | N/A |
| Average True Range (ATR) | 0.59 | 0.63 |
| MACD | 0.21 | 0.16 |
| Stochastic Oscillator | 95.63 | 85.13 |
Opera Ltd is a world-wide internet brand with a large, engaged, and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its browser's features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. Geographically, the company generates maximum revenue from the United States, followed by Singapore, Nigeria, Russia, and other locations.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.